Clarivate™

## Content highlights

**Release date**

2023

Updated annually to reflect Clarivate's expert analysis of the latest major-market events

**Geography**

Global

**Primary and secondary research**

Primary market research includes survey of 60 U.S. payers and interviews with 10 EU5 KOLs.

Extensive secondary research conducted by subject matter experts.

**Key drugs covered**

Admelog/Insulin Lispro Sanofi, Aranesp, Avastin, Basaglar/Abasaglar, Enbrel, Herceptin, Herzuma, Hulio, Humalog, Humira, Inflectra, Kanjinti, Neulasta, Neupogen, Nivestim/Nivestym, Nyvepria, Remicade, Remsima, Rituxan/MabThera, Semglee, Trazimera, Truxima, Udenyca, Zarzio/Zarxio, Ziextenzo

**Content highlights**

Reimbursement and contracting

Access and prescribing

Opportunities and challenges for emerging therapies

# Biosimilars

## Spotlight on Global Access & Reimbursement

### Market outlook

Biosimilar regulations and guidance have been defined, at least in draft form, in most the world's leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA, who first implemented a development framework for biosimilars, but the degree of similarity and granularity varies by country. Payers play a significant role in defining the commercial success of biosimilars—as well as their reference brands—as they decide which products are granted formulary access and preferential reimbursement. As such, it is necessary for biosimilars developers and manufacturers of branded biologics to understand payers' perceptions and attitudes toward biosimilars, which factors influence payer decisions regarding biosimilars, and how these factors vary across different markets.

### Questions answered

- What does the country's biosimilar regulatory pathway dictate, and how does it differ from other markets?
- Is automatic, pharmacy-level substitution permitted?
- How are biosimilars priced and reimbursed?
- Will payers' attitudes toward indication extrapolation restrict use of biosimilars?
- Will payers permit patients to continue current treatment with the reference brand or encourage switching to biosimilars?
- What level of biosimilar discount do payers need to preferentially reimburse a biosimilar and what formulary methods do payers expect to use to stimulate uptake of biosimilars at various price discounts?
- Do payers expect availability of biosimilars to increase the total volume of the drug used?
- What are the key strategies employed to drive biosimilar uptake?

### Product description

Clarivate's *Biosimilars | Access & Reimbursement* provides a detailed view of the regulatory pathways and payer policies for biosimilars in key markets, so you can optimize your market access strategy and determine how to best position your brand to specific stakeholders.

Split in two parts; *Biosimilars | Access & Reimbursement | Global Landscape* provides an overview of the regulations, guidance, pricing and reimbursement environment for biosimilars in the United States, Europe, Japan, and rest of world. *Biosimilars | Access & Reimbursement | US/EU5 Payer Insights* provide deeper insights into the current and future market access environment for biosimilars in the United States and Europe, as well as exploring strategies used in formulary management and expectations on pricing.

**Learn more about Clarivate's full suite of Biosimilars solutions:**

DRG.support@clarivate.com | clarivate.com